
Guru Raghavendra Valicherla

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2960041/publications.pdf

Version: 2024-02-01



Guru Raghavendra

#	Article	IF	CITATIONS
1	Expression, Activity, and Regulation of Phosphorylating Enzymes in Tissues and Cells Relevant to HIV-1 Sexual Transmission. AIDS Research and Human Retroviruses, 2022, 38, 22-32.	1.1	6
2	Evaluation of the Pharmacokinetics of the Pancreastatin Inhibitor PSTi8 Peptide in Rats: Integration of In Vitro and In Vivo Findings. Molecules, 2022, 27, 339.	3.8	2
3	Approaches to minimize the effects of Pâ€glycoprotein in drug transport: A review. Drug Development Research, 2022, 83, 825-841.	2.9	16
4	Elucidation of plasma protein binding, blood partitioning, permeability, CYP phenotyping and CYP inhibition studies of Withanone using validated UPLC method: An active constituent of neuroprotective herb Ashwagandha. Journal of Ethnopharmacology, 2021, 270, 113819.	4.1	11
5	Drug delivery strategies for management of women's health issues in the upper genital tract. Advanced Drug Delivery Reviews, 2021, 177, 113955.	13.7	11
6	Investigating the Contribution of Drug-Metabolizing Enzymes in Drug-Drug Interactions of Dapivirine and Miconazole. Pharmaceutics, 2021, 13, 2193.	4.5	1
7	LC-ESI-MS/MS assay development and validation of a novel antidiabetic peptide PSTi8 in mice plasma using SPE: An application to pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, 2020, 180, 113074.	2.8	5
8	Pancreastatin inhibitor PSTi8 protects the obesity associated skeletal muscle insulin resistance in diet induced streptozotocin-treated diabetic mice. European Journal of Pharmacology, 2020, 881, 173204.	3.5	10
9	Development and validation of LC-MS/MS method for quantification of novel PP2A – β-catenin signalling inhibitor, S011-2111 in mice plasma: Application to its preclinical pharmacokinetic studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1130-1131, 121829.	2.3	4
10	Pancreastatin inhibitor, PSTi8 ameliorates metabolic health by modulating AKT/GSK-3β and PKCλ/ζ/SREBP1c pathways in high fat diet induced insulin resistance in peri-/post-menopausal rats. Peptides, 2019, 120, 170147.	2.4	19
11	Pancreastatin inhibitor PSTi8 attenuates hyperinsulinemia induced obesity and inflammation mediated insulin resistance via MAPK/NOX3-JNK pathway. European Journal of Pharmacology, 2019, 864, 172723.	3.5	17
12	Pancreastatin inhibitor activates AMPK pathway via GRP78 and ameliorates dexamethasone induced fatty liver disease in C57BL/6 mice. Biomedicine and Pharmacotherapy, 2019, 116, 108959.	5.6	35
13	Investigation of the inhibition of eight major human cytochrome P450 isozymes by a probe substrate cocktail in vitro with emphasis on CYP2E1. Xenobiotica, 2019, 49, 1396-1402.	1.1	16
14	Elucidation of pharmacokinetics of novel DNA ligase I inhibitor, S012-1332 in rats: Integration of in vitro and in vivo findings. Journal of Pharmaceutical and Biomedical Analysis, 2019, 162, 205-214.	2.8	11
15	LC-MS/MS method for the simultaneous quantification of luteolin, wedelolactone and apigenin in mice plasma using hansen solubility parameters for liquid-liquid extraction: Application to pharmacokinetics of Eclipta alba chloroform fraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2018. 1081-1082. 76-86.	2.3	33
16	Determination of permeability, plasma protein binding, blood partitioning, pharmacokinetics and tissue distribution of Withanolide A in rats: A neuroprotective steroidal lactone. Drug Development Research, 2018, 79, 339-351.	2.9	10
17	Evaluation of oral pharmacokinetics, in vitro metabolism, blood partitioning and plasma protein binding of novel antidiabetic agent, S009â€0629 in rats. Drug Development Research, 2018, 79, 173-183.	2.9	3
18	Discovery of pancreastatin inhibitor PSTi8 for the treatment of insulin resistance and diabetes: studies in rodent models of diabetes mellitus. Scientific Reports, 2018, 8, 8715.	3.3	30

Guru Raghavendra

#	Article	IF	CITATIONS
19	P-gp modulatory acetyl-11-keto-î²-boswellic acid based nanoemulsified carrier system for augmented oral chemotherapy of docetaxel. Colloids and Surfaces B: Biointerfaces, 2017, 155, 276-286.	5.0	22
20	A Novel Benzocoumarin-Stilbene Hybrid as a DNA ligase I inhibitor with in vitro and in vivo anti-tumor activity in breast cancer models. Scientific Reports, 2017, 7, 10715.	3.3	13
21	Cardioprotective Effect of Ulmus wallichiana Planchon in β-Adrenergic Agonist Induced Cardiac Hypertrophy. Frontiers in Pharmacology, 2016, 7, 510.	3.5	25
22	Phospholipid complexation of NMITLI118RT+: way to a prudent therapeutic approach for beneficial outcomes in ischemic stroke in rats. Drug Delivery, 2016, 23, 3606-3618.	5.7	26
23	Formulation optimization of Docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activity. Scientific Reports, 2016, 6, 26895.	3.3	78
24	Pharmacokinetics and bioavailability assessment of Miltefosine in rats using high performance liquid chromatography tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1031, 123-130.	2.3	15
25	UDP-galactopyranose mutase, a potential drug target against human pathogenic nematode <i>Brugia malayi</i> . Pathogens and Disease, 2016, 74, ftw072.	2.0	6
26	Rutin phospholipid complexes confer neuro-protection in ischemic-stroke rats. RSC Advances, 2016, 6, 96445-96454.	3.6	22
27	Evaluation of anti-hypertensive activity of Ulmus wallichiana extract and fraction in SHR, DOCA-salt- and L-NAME-induced hypertensive rats. Journal of Ethnopharmacology, 2016, 193, 555-565.	4.1	33
28	Metabolic profiling of a novel antithrombotic compound, S002â€333 and enantiomers: metabolic stability, species comparison and <i>in vitro–in vivo</i> extrapolation. Biopharmaceutics and Drug Disposition, 2016, 37, 185-199.	1.9	5
29	No effect on pharmacokinetics of tamoxifen and 4-hydroxytamoxifen by multiple doses of red clover capsule in rats. Scientific Reports, 2015, 5, 16126.	3.3	6
30	Pharmacokinetics, dose proportionality and permeability of S002-333 and its enantiomers, a potent antithrombotic agent, in rabbits. Xenobiotica, 2015, 45, 1016-1023.	1.1	9
31	Molecular Understanding of the Compaction Behavior of Indomethacin Polymorphs. Molecular Pharmaceutics, 2013, 10, 631-639.	4.6	75
32	Pancreastatin is an endogenous peptide that regulates glucose homeostasis. Physiological Genomics, 2013, 45, 1060-1071.	2.3	29
33	Novel lipid based oral formulation of curcumin: Development and optimization by design of experiments approach. International Journal of Pharmaceutics, 2012, 436, 617-623.	5.2	52